Near-infrared Light-responsive Liposomes for Protein Delivery: Towards Bleeding-free Photothermally-assisted Thrombolysis
Overview
Authors
Affiliations
Smart drug delivery systems represent state-of-the-art approaches for targeted therapy of life-threatening diseases such as cancer and cardiovascular diseases. Stimuli-responsive on-demand release of therapeutic agents at the diseased site can significantly limit serious adverse effects. In this study, we engineered a near-infrared (NIR) light-responsive liposomal gold nanorod-containing platform for on-demand delivery of proteins using a hybrid formulation of ultrasmall gold nanorods (AuNRs), thermosensitive phospholipid (DPPC) and non-ionic surfactant (Brij58). In light-triggered release optimization studies, 55.6% (± 4.8) of a FITC-labelled model protein, ovalbumin (MW 45 kDa) was released in 15 min upon NIR irradiation (785 nm, 1.35 W/cm for 5 min). This platform was then utilized to test on-demand delivery of urokinase-plasminogen activator (uPA) for bleeding-free photothermally-assisted thrombolysis, where the photothermal effect of AuNRs would synergize with the released uPA in clot lysis. Urokinase light-responsive liposomes showed 80.7% (± 4.5) lysis of an in vitro halo-clot model in 30 min following NIR irradiation (785 nm, 1.35 W/cm for 5 min) compared to 36.3% (± 4.4) and 15.5% (± 5.5) clot lysis from equivalent free uPA and non-irradiated liposomes respectively. These results show the potential of low-dose, site-specific thrombolysis via the combination of light-triggered delivery/release of uPA from liposomes combined with photothermal thrombolytic effects from gold nanorods. In conclusion, newly engineered, gold nanorod-based, NIR light-responsive liposomes represent a promising drug delivery system for site-directed, photothermally-stimulated therapeutic protein release.
Liposomal Formulations: A Recent Update.
Agrawal S, Baliga V, Londhe V Pharmaceutics. 2025; 17(1).
PMID: 39861685 PMC: 11769406. DOI: 10.3390/pharmaceutics17010036.
Vidallon M, Moon M, Liu H, Song Y, Crawford S, Teo B ACS Appl Mater Interfaces. 2024; .
PMID: 39360874 PMC: 11492166. DOI: 10.1021/acsami.4c12024.
Nazemidashtarjandi S, Larsen B, Cheng K, Faulkner S, Peppas N, Parekh S Acta Biomater. 2024; 183:61-73.
PMID: 38838911 PMC: 11514431. DOI: 10.1016/j.actbio.2024.05.052.
Zhang Q, Huang S, Liu X, Wang W, Zhu Z, Chen L Int J Nanomedicine. 2024; 19:3715-3735.
PMID: 38681090 PMC: 11046314. DOI: 10.2147/IJN.S462194.
Ultrasound Trigger Ce-Based MOF Nanoenzyme For Efficient Thrombolytic Therapy.
Shan J, Du L, Wang X, Zhang S, Li Y, Xue S Adv Sci (Weinh). 2024; 11(20):e2304441.
PMID: 38576170 PMC: 11132072. DOI: 10.1002/advs.202304441.